A high-growth biotech with approximately 69% revenue expansion and significant analyst-implied upside that is simultaneously running a deeply negative cash burn, trading in a confirmed downtrend below a declining 200-day average, and carrying 26% short interest — a high-risk, binary-outcome setup where execution consistency must improve before the risk/reward becomes actionable.
Thesis pillars
- Death Cross Confirmed Downtrend↑Improving
- Catastrophic Cash Burn Runway Risk→Stable
- High Short Interest Options Skepticism↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 12, 2026
CRISPR Therapeutics AG (CRSP) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $54.11: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality.
CRISPR Therapeutics AG develops gene-editing therapies using CRISPR/Cas9 technology, with one approved product — CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia — commercialized jointly with Vertex Pharmaceuticals. Revenue comes entirely from a 40%... Read more
Sell if holding. Engine safety override at $54.11: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on news soft leadership change. Suitability: speculative.
About CRISPR Therapeutics AG
About CRISPR Therapeutics AG
CASGEVY, the first approved CRISPR-based gene therapy, received marketing authorizations for sickle cell disease and transfusion-dependent beta thalassemia in the United States, EU, Great Britain, Canada, Switzerland, and six Middle Eastern countries by 2025 year-end. CRISPR Therapeutics AG holds a 40% economic interest in CASGEVY through its Vertex collaboration, but that revenue share was insufficient to cover the company's 40% share of program costs. Cash, equivalents, and marketable securities were approximately $1.975 billion at December 31, 2025, projected sufficient for at least 24 months.
Revenue flows from CRISPR Therapeutics' 40% share of CASGEVY net sales, which Vertex Pharmaceuticals leads in commercializing across approved markets targeting an estimated 60,000 patients with severe sickle cell disease or transfusion-dependent beta thalassemia in the U.S., Canada, Europe, and parts of the Middle East. Prior to 2025, annual CASGEVY program cost exposure was capped at $110.3 million under a deferral provision in the Vertex agreement; that provision expired at the start of 2025, raising the company's cost burden. Beyond hemoglobinopathies, CRISPR Therapeutics is advancing in vivo liver-editing candidates including CTX310 (Phase 1b for ANGPTL3) and CTX340 (for hypertension), a CAR T program featuring zugocabtagene geleucel in Phase 1/2 for autoimmune disease and hematologic malignancies, and an siRNA collaboration with Sirius Therapeutics entered in May 2025. Manufacturing for zugocabtagene geleucel is conducted at the company's internal GMP facility in Framingham, Massachusetts.
Show full overview
The company's near-term financial trajectory depends on whether CASGEVY commercial uptake can offset the expanded cost burden, and on whether CTX310 or zugocabtagene geleucel can advance to registrational trials. No in vivo gene-editing therapy had been approved in the U.S. or EU as of the 10-K date, subjecting CRISPR Therapeutics' in vivo programs to a novel regulatory pathway without established precedent. The 10-K discloses that CASGEVY program expenses are expected to exceed the company's 40% revenue share for the foreseeable future — a dynamic that, if uptake ramps slower than projected, could require additional capital before the 24-month runway expires.
See also: Healthcare · Biotechnology
From CRISPR Therapeutics AG's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-29Recent Developments — CRISPR Therapeutics AG
Latest news
- NEWS Resignation of CRISPR Therapeutics CFO — fiscal.ai Oct 23, 2026 negative
- NEWS CRISPR Therapeutics Appoints A. J. Silver CFO, Effective Immediately, Succeeding Raju Prasad — benzinga Oct 19, 2026 neutral
- NEWS UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52 — benzinga Oct 15, 2026
- NEWS CRISPR Therapeutics To Present Phase 1b Data For CTX310 In Severe Hypertriglyceridemia In Late-Breaking AHA Presentation — benzinga Oct 8, 2026 positive
- NEWS Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an — benzinga Oct 6, 2026 neutral
Generated 2026-10-29T11:53:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $54.11: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $50.32. Score 5.1/10, moderate confidence.
Analyst target: $77.07 (+42.4% upside). Prior stop was $50.32. Stop-loss: $50.32.
Quality below floor (1.8 < 4.0).
CRISPR Therapeutics AG trades at a P/E of N/A (forward -15.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
28 analysts cover CRSP with a consensus score of 3.8/5. Average price target: $86.
What does CRISPR Therapeutics AG do?CRISPR Therapeutics AG develops gene-editing therapies using CRISPR/Cas9 technology, with one approved product —...
CRISPR Therapeutics AG develops gene-editing therapies using CRISPR/Cas9 technology, with one approved product — CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia — commercialized jointly with Vertex Pharmaceuticals. Revenue comes entirely from a 40% share of CASGEVY product sales under the Vertex collaboration, which did not cover program expenses in 2025; cash, equivalents, and marketable securities were approximately $1.975 billion at December 31, 2025.